

Rheumatoid arthritis (update) committee meeting 8

Date: 05/07/2017

Location: Boardroom, NGC, 180 Great Portland Street, London, W1W 5QZ

Minutes: Confirmed

NICE National Institute for
Health and Care Excellence

Committee members present:		
Stephen Ward (SW, Chair)		(Present for notes 1–5)
Ann Bevan (ABe)		(Present for notes 1–5)
Ailsa Bosworth (ABo)		(Present for notes 1–5)
Vicky Chamberlain (VC)		(Present for notes 1–5)
Jennie Jones (JJ)		(Present for notes 1–5)
Bruce Kirkham (BK)		(Present for notes 1–5)
Hilary McKee (HMK)		(Present for notes 1–5)
Frank McKenna (FMK)		(Present for notes 1–5)
Heidi Siddle (HS, via WebEx)		(Present for notes 1–4D)
Louise Warburton (LW)		(Present for notes 1–5)

In attendance:		
Anne-Louise Clayton	Editor, NICE	(Present for notes 4D–5)
Caroline Keir	Guideline Commissioning Manager, NICE	(Present for notes 1–5)
Alex Allen	Senior Research Fellow, NGC	(Present for notes 1–5)
Serena Carville	Guideline Lead/Associate Director, NGC	(Present for notes 1–5)
Meredith Faust	Document Editor/Process Assistant, NGC	(Present for notes 1–5)
Sophia Kemmis-Betty	Senior Health Economist, NGC	(Present for notes 1–5)
Jacqui Real	Senior Research Fellow, NGC	(Present for notes 1–4E)

Apologies:

Lina Gulhane (LG)	Senior Information Scientist, NGC
Anupama Nandagudi (AN)	Consultant Rheumatologist
Benjamin Parker (BPa)	Consultant Rheumatologist
Ben Pordes (BPo)	Senior Project Manager, NGC
Grit Scheffler-Ansari (GSA)	Research Fellow, NGC

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the eighth meeting on rheumatoid arthritis. The committee members and attendees introduced themselves.

No members of the public asked to observe the meeting.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included monitoring evidence reviews.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was monitoring people with rheumatoid arthritis.

The Chair asked everyone to declare verbally any interests that have arisen since the last meeting. There were no new declarations of interest.

The Chair and a senior member of the Developer’s team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the committee if they wanted any changes made to the minutes of the last meeting. The committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Presentations and discussion

A. JR presented the data for the following review question: In adults with rheumatoid arthritis, what is the optimum frequency of disease activity monitoring (outside of the annual review)?

<p>i. SKB presented the health economic evidence related to the above review question.</p> <p>B. JR presented the data for the following review question: In adults with rheumatoid arthritis, what is the best target to use when monitoring disease activity (remission or low disease activity)?</p> <p>C. JR presented the updated data for the following review question: In adults with rheumatoid arthritis, what is the clinical and cost effectiveness of a treat-to-target management strategy compared with usual care?</p> <p>i. SKB presented the health economic evidence related to the above review question.</p> <p>D. The committee drafted monitoring recommendations based on the evidence presented in the reviews above.</p> <p>E. The committee reviewed and updated the recommendations and rationale for DMARD usage.</p>
<p>5. Any other business</p>
<p>None.</p>

Date of next meeting: 12/09/2017

Location of next meeting: National Guideline Centre, 180 Great Portland Street, London W1W 5QZ